Stockscreener 앱 받기
1.78
3.78%
-0.07
전일 마감가:
$1.85
열려 있는:
$1.814
하루 거래량:
29,557
Relative Volume:
0.11
시가총액:
$17.38M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-2.3733
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
-10.55%
1개월 성능:
-17.97%
6개월 성능:
-22.27%
1년 성능:
-81.64%
1일 변동 폭
$1.78
$1.90
1주일 범위
$1.70
$2.07
52주 변동 폭
$1.17
$9.858
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.78 | 18.07M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
Inmune Bio Inc Advances CORDStrom and XPro1595 Regulatory Pathways - TradingView
Annovis Bio, Inc. Secures DSMB Approval for Phase 3 Trial - TradingView
Upstream Bio posts mid-stage asthma trial win (UPB:NASDAQ) - Seeking Alpha
Upstream Bio, Inc. Reports Positive Phase 2 VALIANT Trial Results for Verekitug - TradingView
Severe asthma trial: experimental drug cuts attacks up to 56% - Stock Titan
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma - The Manila Times
What’s the outlook for Third Harmonic Bio Inc.’s sectorWeekly Trade Review & Entry Point Confirmation Alerts - mfd.ru
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer - GlobeNewswire Inc.
KALA BIO (KALA) names director Avi Minkowitz CEO and CFO as David Lazar steps down - Stock Titan
Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewswire
Biotech Climb Bio to field questions at Guggenheim, Oppenheimer, Leerink events - stocktitan.net
GRI Bio Reiterates Full Year 2025 Financial Results, - GlobeNewswire
Entera Bio (NASDAQ: ENTX) widens OPKO partnership and appoints Steven Rubin to board - Stock Titan
KALA BIO Signs Securities Purchase Agreement With Series AAA Investors - TradingView
Tevogen Bio Holdings Inc Evaluates Special Cash Dividend - TradingView
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? - Yahoo Finance
GRI Bio (GRI) expands at-the-market equity program to $60M capacity - Stock Titan
Annovis Bio, Inc. Announces Progress in Alzheimer's and Parkinson's Trials - TradingView
GRI Bio, Inc. Announces Positive Phase 2a Clinical Trial Data for GRI-0621 - TradingView
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - TradingView
Alzheimer’s trial signal and rare skin disease cell therapy at INmune Bio - Stock Titan
Korro Bio, Inc. Unveils KRRO-121 as a Potential First-in-Class Treatment - TradingView
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures - GlobeNewswire
BofA Securities initiates coverage on Belite Bio stock with Buy rating - Investing.com
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
CEO shake-up at Zura Bio (NASDAQ: ZURA) with new director added - Stock Titan
KALA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance UK
GRI Bio (NASDAQ: GRI) plans 1-for-28 reverse stock split in January - stocktitan.net
GRI Bio slashes share count with 1-for-28 split to meet Nasdaq price rule - Stock Titan
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Insider Monkey
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Insider Monkey
Access Bio Inc To Acquire 57 Billion Won Worth Of Shares And Majority Stake In Rfbio Co Ltd - TradingView
Palisade Bio Announces Two Abstracts Selected for Poster - GlobeNewswire
GRI Bio (NASDAQ: GRI) approves reverse split to support Nasdaq equity - Stock Titan
GRI Bio Regains Conditional Compliance With Nasdaq Listing Requirements - TipRanks
Layoff Tracker: Lyra Shutters, EMD Serono Downsizes - BioSpace
Nuvation Bio Signs License and Collaboration Agreement With Eisai - TradingView — Track All Markets
Cabaletta Bio, Inc. Announces 2026 Strategic Priorities - TradingView — Track All Markets
Zura Bio Ltd Announces Corporate and Clinical Updates for 2026 - TradingView — Track All Markets
GRI Bio, Inc. Increases Share Issuance Limit - TradingView — Track All Markets
Can Boundless Bio Inc. stock double in next 5 yearsPortfolio Return Report & Expert Verified Movement Alerts - Улправда
Is Nuvation Bio Inc. stock safe for conservative investorsMarket Risk Report & Daily Momentum Trading Reports - Улправда
Is Mustang Bio Inc. stock positioned for long term growthQuarterly Trade Review & Growth-Oriented Investment Plans - ulpravda.ru
Mercury Bio Launches MB-TIP™--Revolutionizing Immunotherapy with Intracellular Targeting - WV News
GRI Bio, Inc. Announces Positive Phase 2a Trial Data for GRI-0621 - TradingView — Track All Markets
GRI Bio Announces Additional Positive Data from Phase 2a - GlobeNewswire
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - TradingView — Track All Markets
Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
New drug trials target lupus and kidney disease, with 2026 data ahead - Stock Titan
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):